Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
There are many patients who do not respond to immune checkpoint inhibitor (ICI) immunotherapy. Here, the authors show a significant negative correlation between sphingosine kinase-1 (SK1) expression and survival for ICI-treated melanoma patients, and further show that targeting SK1 improves response...
Main Authors: | Caroline Imbert, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, Elodie Martin, Florie Bertrand, Marlène Marcellin, Odile Burlet-Schiltz, Anne Gonzalez de Peredo, Virginie Garcia, Stéphane Carpentier, Sophie Tartare-Deckert, Pierre Brousset, Philippe Rochaix, Florent Puisset, Thomas Filleron, Nicolas Meyer, Laurence Lamant, Thierry Levade, Bruno Ségui, Nathalie Andrieu-Abadie, Céline Colacios |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-14218-7 |
Similar Items
-
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
by: Florie Bertrand, et al.
Published: (2017-12-01) -
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
by: Fatima Bilal, et al.
Published: (2019-04-01) -
Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy
by: Anne Montfort, et al.
Published: (2019-10-01) -
The TNF Paradox in Cancer Progression and Immunotherapy
by: Anne Montfort, et al.
Published: (2019-07-01) -
Anti-TNF, a magic bullet in cancer immunotherapy?
by: Anne Montfort, et al.
Published: (2019-11-01)